RxDoctor Payments Data

Richard Berger, DO

Family Medicine · Philadelphia, PANPI 1740296615

Payments from drug & device makers

$11,196in general payments, 2019–2025

Across 662 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$538
  • Exact Sciences$474
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$11,190100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,196 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$66,912
Medicare patients
196
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban160$126,861
OzempicSemaglutide58$56,550
JardianceEmpagliflozin68$51,399
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$47,879
FarxigaDapagliflozin Propanediol53$37,621
JanuviaSitagliptin Phosphate41$33,858
CaplytaLumateperone Tosylate15$24,136
MyrbetriqMirabegron37$20,032
OxycontinOxycodone Hcl24$19,281
LinzessLinaclotide35$18,557
EntrestoSacubitril/Valsartan20$18,512
TrulicityDulaglutide15$15,926
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$15,421
TradjentaLinagliptin29$15,205
Breo ElliptaFluticasone/Vilanterol26$14,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$443$129,303172 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta, Combivent Respimat$538$93,068153 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,141$70,007113 claims
Novo NordiskOzempic$1,016$56,55058 claims
AstraZenecaFarxiga$1,128$37,62153 claims
MerckJanuvia$138$33,85841 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$361$24,13615 claims
Astellas Pharma US IncMyrbetriq$249$20,03237 claims
AbbVieLinzess$2,055$18,55735 claims
NovartisEntresto$123$18,51220 claims
Lilly USA, LLCTrulicity$296$15,92615 claims
Johnson & JohnsonXarelto$90$13,76821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →